Skip Navigation
Skip to contents

Perspect Integr Med : Perspectives on Integrative Medicine



Page Path
HOME > Perspect Integr Med > Volume 2(1); 2023 > Article
Review Article
Proposal of a Case Reporting Draft Guideline for Pharmacopuncture: Literature Review of Pharmacopuncture Case Reports
Soohyun Jeong1,†orcid, Chaeyeon Son1,†orcid, Hyunjin Kim1orcid, Gapsik Yang1orcid, Hongmin Chu2,3orcid, Jungtae Leem3,*orcid
Perspectives on Integrative Medicine 2023;2(1):24-35.
Published online: February 21, 2023

1College of Korean Medicine, Woosuk University, Jeonju, Republic of Korea

2Wollong public health subcenter, Paju public health center, Paju, Republic of Korea

3College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea

*Corresponding author: Jungtae Leem, College of Korean Medicine, Wonkwang University, 460, Iksan-daero, Sin-dong, Iksan, Jeollabuk-do, Republic of Korea, E-mail:
† The authors contribute equally.
• Received: November 6, 2022   • Revised: January 2, 2023   • Accepted: January 11, 2023

©2023 Jaseng Medical Foundation

This is an open access article under the CC BY-NC license (

  • 42 Download
  • Pharmacopuncture is a popular treatment that combines the advantages of both herbal medicine and acupuncture. However, pharmacopuncture care reporting guidelines have not yet been developed. This study aimed to propose a reporting guideline draft for pharmacopuncture case reports. Pharmacopuncture case reports were retrieved from 4 databases (KCI, RISS, ScienceON, OASIS) to analyze the items reported and their fidelity. We analyzed 5 existing reporting guidelines related to Korean medicine case reporting to identify the items to be included in the extension of pharmacopuncture reporting guidelines. From 3,684 studies, 29 case reports were included and 4 items were identified as not reported in enough detail: “direction and depth of pharmacopuncture” (89.5%); “method of manufacturing the syringe needle” (82.8%); “posture of the patient during the therapy” (75.9%); and “pharmacopuncture recipe” (69.5%). As a result of analyzing moxibustion and acupuncture clinical trial reporting guidelines, it was determined that detailed reporting guidelines on the type of pharmacopuncture, manufacturing method, and treatment method were required and we propose that a pharmacopuncture reporting guideline draft should include these details. Further investigations are warranted using the Delphi technique to reach agreement with clinical practitioners and clinical research experts.
Pharmacopuncture is a Korean medicine intervention where purified herbal extracts are injected into disease/condition-related acupoints. It was introduced into the field of Korean medicine in the mid/late 1990s, and through a variety of research activities has been reported to achieve remarkable treatment success [1,2]. Despite the wide acceptance of pharmacopuncture in clinical practice due to its multiple advantages (wide application range, rapid effect through intramuscular or intradermal injections, and low side effects [1,2]), there are not many high-quality evidence-based studies.
Case reporting is an important method of retrospective research with detailed descriptions of new features of medical issues, symptoms, diagnosis, or therapy [3]. A case report provides detailed descriptions of symptoms and diagnosis, as well as optimized intervention based on them. Its clinical reproducibility allows the same treatment in patients with similar conditions. In addition to these advantages, case reports also help practitioners better understand important medical discoveries that can be overlooked in research methodologies such as clinical trials [3,4]. In addition, the research questions presented in a case report can be used as hypotheses for follow-up research with a high level of evidence, and often becomes the starting point of a range of follow-up studies [5]. However, among the reported cases of pharmacopuncture, there are large variations in the reported items and quality of reporting. There are currently no standardized guidelines for pharmacopuncture case reporting.
Given the nature of case reporting, through which the researcher can elaborate on the issue in any desired detail, efforts have been made to establish case reporting guidelines to ensure more objective information transfer within a standardized framework. As a result, the CAse REports (CARE) guidelines [3,4] were developed to support the reporting of various clinical cases. The CARE [3,4] guidelines, which use a checklist developed in 2013 consisting of 13 items to improve the quality of case reporting, was the first guideline that covered detailed items for case reporting [4,6]. In the field of Korean medicine, reporting guidelines are currently available for interventions such as acupuncture, herbal medicine, and moxibustion: (1) STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) [7], reporting guidelines for randomized controlled trials (RCTs) on acupuncture intervention; (2) STandards for Reporting Interventions in Clinical Trials of Moxibustion (STRICTOM) [8], which covers acupuncture and Korean medicine interventions with moxibustion application; (3) case report in Chinese medicine (CARC) [9], case reporting guidelines for acupuncture and herbal medicine interventions; and (4) case report for Sasang medicine (CARES) [10], case reporting guidelines for Four-Constitution Medicine [CARE + S standing for Sasang (Four Constitution) Medicine].
The development of case reporting guidelines comes with the advantage of enhancing the reporting rate, as demonstrated by the report of the improved quality of reports in studies conducted after the development of case reporting guidelines [11]. The study “Assessment of the Quality of Reporting on Case Reports in the Journal of Sasang Constitutional Medicine from June 2018 to December 2021: Using CARE Guideline” [11] published in 2022 in the Journal of Sasang Constitutional Medicine compared the quality of the studies published during the five-year period before and after the publication of the CARE guidelines with 2018 as the reference year. This study determined that the reporting rate assessed as “sufficient” increased by 7.8% and those assessed as “insufficient” and “unreported” decreased by 4.1% and 3.5%, respectively, in the years following the publication of the CARE guidelines. This demonstrated the significant positive effect of case reporting guidelines on the quality of case reports.
However, case reporting guidelines for pharmacopuncture interventions have yet to be developed. While admitting that the aforementioned guidelines can also be used for writing pharmacopuncture case reports, development of pharmacopuncture case reporting guidelines is required. Standardized reporting guidelines are needed to consider the complex properties of pharmacopuncture which have the attributes of both acupuncture and herbal medicine. Therefore, the aim was to improve the quality of pharmacopuncture case reports by examining the literature to develop pharmacopuncture-specific case reporting guidelines. The goal was to propose the items to be included in the development of pharmacopuncture case reporting guidelines to improve the quality of case reporting in the future. To this end, pharmacopuncture case report studies were selected for review and the items reported were extracted. Existing reporting guidelines for Korean medicine intervention, such as acupuncture, herbal medicine, and moxibustion, were reviewed to gather essential items that should be included in pharmacopuncture case reporting guidelines.
1. Data collection
In terms of dosage and procedure, “pharmacopuncture,” which is extensively used in Korea, differs slightly from “herbal injection,” which is utilized as an intravenous injection method in China. Therefore, the scope of this review was limited to “pharmacopuncture” research. The search was also confined to databases of Korean studies, which mostly reported cases of Korean pharmacopuncture. Four electronic databases were searched for relevant studies published over the past five years up to August 1, 2022: Oriental Medicine Advanced Searching Integrated System (OASIS), ScienceON, Research Information Sharing Service (RISS), and Korea Citation Index (KCI). To retrieve case reports on pharmacopuncture intervention the search terms used were “pharmacopuncture” and “yakchim[Korean]” in OASIS and “(yakchim[Korean]|bongdokyakchim[Korean]|bongdok[Korean]| pharmacopuncture|aquacupuncture|acupoint-injection|acupuncture-point-injection|pharmaco-acupucture|hydro-acupucture|herbal-medicine-injection|traditional-medicine-injection|bee|bee-venom|apitherapy|apitoxin)” in ScienceON, RISS, KCI databases.
2. Inclusion and exclusion criteria

2.1. Inclusion criteria

The inclusion criteria were case reports on a single pharmacopuncture intervention case using a single or composite material produced in Korea.

2.2. Exclusion criteria

Studies excluded from this study: (1) No relevance to pharmacopuncture; (2) Not a single case; (3) Korean pharmacopuncture materials not used (e.g., materials from China or Japan); and (4) No source documents.
For case reports covering complex interventions without focusing on pharmacopuncture, the decision on inclusion or exclusion was made after a full-text review.
The term “case series” describes the treatment of numerous patients, and the description of pharmacopuncture treatment may be less extensive than that of a single patient’s “case report.” Therefore, in this study, only the “case report” of a single patient was included, whereas the “case series” was excluded.

2.3. Literature search

As a result of the literature search, a total of 3,684 studies were retrieved from the four databases. After removing duplicates, 2,307 studies remained. In the title and abstract review, 1,709 studies were deemed “not related to the topic,” leaving 411 studies to be reviewed in full. A total of 29 studies were included in this review (Fig. 1).

2.4. Data collection and analysis

There were 29 case reports selected and reviewed to derive basic information and pharmacopuncture-related details. Patient demographics including age, disease/condition, and non-pharmacopuncture interventions were determined for further analysis. Classification of disease/condition was performed according to the 9th edition of the Korean Standard Classification of Diseases (KCD-9). Pharmacopuncture-related details which were examined included: pharmacopuncture type, manufacturing methods, manufacturing facilities, ingredients and composition, needling location, dose, injection method, and intervention period.
Furthermore, reporting guidelines related to Korean medicine interventions were retrieved and reviewed. There were three cases reporting guidelines and two clinical trial reporting guidelines for reporting Korean medicine interventions. The case reporting guidelines were CARE [3,4], which proposes general guidelines, and CARES [10], which extends CARE by adding Four-Constitution Medicine, and CARC [9], which covers Chinese herbal medicine and acupuncture interventions. The clinical trial reporting guidelines for reporting Korean medicine interventions were STRICTA [7] related to acupuncture, and STRICTOM [8] related to moxibustion were selected.
The contents were organized based on the report items of each reporting guideline, and items that were omitted, or that showed characteristics of medicinal acupuncture were identified and further supplemented. As guidelines for Korean medicine intervention, acupuncture-related STRICTA [7] and moxibustion-related STRICTOM [8] were selected as RCT reporting guidelines Each of these clinical reporting guidelines were classified centering on the report items, and complemented missing items and the items representing the characteristics of pharmacopuncture were additionally considered.
1. General characteristics of the included studies
In the 29 case-reporting studies that used pharmacopuncture as a primary intervention, all age groups were distributed relatively evenly, with studies involving patients in their 40s and 50s accounting for the highest proportion (n = 6 each, 20.7%). The diseases/conditions mentioned in the 29 case reports were classified according to KCD-9. Musculoskeletal and nervous system disorders were the most frequently reported (n = 7, 24.1% each), followed by disorders of the digestive system and not classified (n = 3, 10.3% each). Fourteen types of pharmacopuncture were used in the 29 studies. Bee venom pharmacopuncture was the most frequently used (n = 13, 44.8%), followed by Hwangryeonhaedoktang pharmacopuncture (n = 5, 17.2%). Fifteen different types of non-pharmacopuncture interventions were mentioned in 29 studies. Herbal medicine was the most frequently used concomitant intervention mentioned in 24 studies (82.8%), followed by acupuncture in 23 studies (79.3%; Table 1 [1240], Supplementary Table 1).
2. Analysis of the current status of reporting of pharmacopuncture-related items
All pharmacopuncture-related items reported in the selected 29 papers are outlined in Supplementary Table 2 [1240]. Pharmacopuncture manufacturing methods, ingredients and composition, patient’s posture during the therapy, needling direction and depth were not mentioned in over 50% of the studies reviewed.
3. A proposal for extending pharmacopuncture case reporting guidelines based on comparative analysis of existing reporting guidelines
CARE [3,4], its extended version CARES [10], and CARC [9] guidelines cover 19 items, which include the Title, Keywords, Abstract, Introduction, Patient Information, Clinical Findings, Diagnostic Assessment, Therapeutic Intervention, Outcome, Follow-up, Discussion, and Informed Consent. CARC [9] guidelines cover three items (Advice and precautions, References, and Figures/Tables) that are not covered in the CARE and CARES guidelines, but it does not cover the timeline which is covered in the CARE and CARES guidelines. It also provides in-depth descriptions of traditional medicine interventions including herbal intervention, acupuncture, electropuncture, and moxibustion. For these items, the CARC guidelines speculate the case reporting requirements more elaborately; in case of herbal intervention for example, items are presented in divisions of proprietary medicine and self-prepared herbal intervention. The CARC guidelines also include the quality control standard in the report items, and distinguishes between integrated treatments (including herbal intervention, acupuncture, electropuncture, and moxibustion), and non-integrated treatments in the item settings.
The focus of the Consolidated Standards of Reporting Trials (CONSORT)-based STRICTA [7] and STRICTOM [8] guidelines are not on general case-reporting issues, but on specific treatment interventions. For example, items related to the formal aspects of case reporting, such as keywords, abstract, and introduction, are not included. Except for “Precaution Measures” in the STRICTOM [8] guidelines, both provide intervention-related regulations in great detail and present six items regarding treatment interventions: Treatment Rationale, Details of Treatment, Treatment Regimen, Other Components of Treatment, Practitioner Background, and Control and Comparator Intervention. The item covered only by STRICTOM [8] guidelines, i.e., Precaution Measures, recommends that if precaution measures are provided, they should be reported in full detail. These two guidelines share the overall aspects, but contain contents modified to suit the characteristics of each intervention under the item “Details of Treatment.” For example, the STRICTA [7] guidelines require the time of needle retention and needle stimulation, whereas the STRICTOM [8] guidelines require the specifications of the materials used for moxibustion and the procedure and technique for moxibustion (Table 2 [7,8]).
This study aimed to propose a draft of pharmacopuncture case reporting guidelines. Existing pharmacopuncture case reports and case-reporting guidelines for Korean medicine intervention were analyzed with a view to accumulating high-quality pharmacopuncture case reports and preparing the clinical research framework for future research. To this end, we reviewed 29 eligible studies to determine the current status of pharmacopuncture case reporting in Korea. The analysis revealed that pharmacopuncture case reports do not properly consider necessary items related to detailed contents of pharmacopuncture intervention. After pooling the analysis results of the case reports and those of case-reporting guidelines for Korean medicine therapies, we derived the following report items that should be included in a pharmacopuncture case report: (1) Treatment Rationale–pharmacopuncture type; and (2) Details of Treatment–number of points treated during a treatment session, total dose per treatment session and single dose per point, acupoint names (muscle or anatomical location) and the rationale for selection, needling depth and direction, patient’s posture during the therapy, treatment environment, pharmacopuncture procedure and technique, and responses sought (patient’s perception or adverse effects).
Pharmacopuncture is a Korean medicine intervention technique that combines the advantages of acupuncture (physical stimulation) and herbal medicine (biochemical effects). It was admitted into insurance scheme in 2001 under the National Health Insurance Act, but was excluded from insurance coverage in 2006. Later, it was included in the automobile insurance medical fee system. Park et al [41] conducted a survey in 2018 in 393 Korean medicine doctors on the clinical practice of pharmacopuncture therapy, and reported that 88% of the respondents had experience of administering a pharmacopuncture intervention and that pharmacopuncture was being widely used in the clinical setting. From the results of this study the characteristics of the clinical application of pharmacopuncture could also be confirmed, albeit indirectly.
Analysis of the patient age distribution in the selected 29 pharmacopuncture case reports revealed that patients in their 40s and 50s accounted for 41% of cases (6 studies and 20.7% each, 12 studies and 41.4% together). According to a basic report on the status of Korean medicine utilization in 2020, outpatients in their 60s and over, accounted for the highest proportion of cases treated (35.5%), followed by the patients in their 50s (22.4%), and 40s (17.9%), which is consistent with the patient ratios analyzed in the current study.
As a result of classifying the diseases/conditions treated in the case studies using KCD-8, there were seven studies each (24.1%) for musculoskeletal and nervous system disorders and these diseases/conditions were identified as the cases that received the highest clinical application of pharmacopuncture. In addition, pharmacopuncture was used in treating various diseases/conditions such as digestive system diseases/conditions, injury and poisoning and certain other consequences of external causes, neoplasms, psychiatric and behavioral disorders, and skin and subcutaneous tissue system disorders. The clinical treatment frequency reported in a study conducted by Park et al [41] was similar to that of this study: musculoskeletal disorders (41.7%), nervous system disorders (18.0%), and digestive system disorders (9.0%).
In the classification of pharmacopuncture interventions 14 different types of pharmacopuncture were used 37 times in the 29 cases reviewed. Among these 14 pharmacopuncture types, bee venom pharmacopuncture was used most frequently (n = 13, 44.8%), accounting for close to half the total pharmacopuncture interventions. Bee venom pharmacopuncture was reportedly first used in 168 B.C. in a primitive form, as recorded in an ancient Korean medicine book, and has been used ever since in clinical practice [42]. It has a broad application field including musculoskeletal and nervous system disorders, which explains why bee venom pharmacopuncture occupied the highest proportion among the 14 different types of pharmacopuncture [43].
The proportion of ND, i.e., not described in the case report, exceeded 50% in four out of 12 items related to pharmacopuncture case reporting: needling direction and depth (89.7%), pharmacopuncture manufacturing methods (82.8%), patient’s posture during the therapy (75.9%), and pharmacopuncture ingredients and composition (69.0%). Another four items had the proportions of ND exceeding 20%: the diameter, length, and manufacturer of the needle used for treatment (34.5%, 37.9%, and 24.1%, respectively), and the total dose administered per treatment session (24.1%). A quality assessment performed by applying the existing reporting guidelines revealed that the study by Son et al [44], which performed quality assessment of acupuncture therapy in compliance with the recommendation of the STRICTA guidelines, had low reporting ratios of literature sources, depth of injection, details of other interventions, and description of acupuncturists’ professional affiliation. Kim et al [45] assessed the quality of reporting on moxibustion therapy which was in compliance with the recommendation of the STRICTOM [8] guidelines, and reported that moxibustion-related studies had low reporting ratios in treatment protocol setting and context, patient information, explanation to patients, and responses sought (e.g., warm feeling, skin reddening, stinging pain). Insufficient or improper reporting of the above items pertaining to the category of “details of treatment” can lower the likelihood of clinical application, which is an important objective of case reporting [46]. Such case studies also attract less follow-up research. Therefore, there is a compelling need to standardize the pharmacopuncture case reporting process by detailing the reporting standards for these items in pharmacopuncture case reporting guidelines. Another important finding of this study was that pharmacopuncture therapy was rarely administered as a single intervention, as demonstrated by the high proportions of non-pharmacopuncture concomitant interventions. For example, herbal medicine and acupuncture were used in 24 (82.8%) and 23 studies (79.3%), respectively, as the most widely used concomitant interventions, and a variety of other concomitant interventions were also used, including moxibustion, cupping, electropuncture, and Western medicine and physiotherapy. Therefore, it is also essential to include the reporting of concomitant interventions other than pharmacopuncture in pharmacopuncture case reporting guidelines.
Case reporting refers to describing a specific case believed to have medicinal value such as a new clinical discovery, i.e., a new symptom or treatment method for a specific disease/condition, and the related clinical course [5,6]. Major advantages of case reports include the reproducibly of treatment modalities, the important role they play for case-based medical education and medical textbooks which may result from them, and they provide the basis for studies with a high level of evidence [5]. However, since they are written in subjectively by the individual clinician, the research quality is not homogeneous across case reports and depends on their own observations or insights [47,48]. There has been a constant demand to establish the standards for case reporting aiming upward for the standardization of the quality of case studies [49]. Currently, the available clinical study reporting guidelines include the CARE [3,4] guidelines for clinical case reporting, the CONSORT [50] guideline checklist for randomized controlled trials (RCTs), the Strengthening the Reporting of Observational studies in Epidemiology [51] guidelines for observational studies, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [52] guideline checklist for systematic literature reviews and meta-analyses. Various reporting guidelines for Korean medicine interventions have also been developed, such CARE [3,], CARES [10] (extended edition of CARE), CARC [9], STRICTA [7], and STRICTOM [8] (extended editions of CONSORT [50]). The Template for Intervention Description and Replication guideline [53] is used for reporting complex interventions, which suits the characteristics of Korean medicine therapies using a variety of interventions in an integrated manner. In the field of Korean medicine, the need for intervention-specific reporting guidelines is constantly being raised.
Of the aforementioned five reporting guidelines related to Korean medicine interventions, the CARE [3,4] guidelines, its extended edition CARES [10] (added by Four-Constitution Medicine), and the CARC [9] guidelines, provide general descriptions of Korean medicine interventions such as acupuncture and moxibustion, and mention general features of case reporting, unlike the STRICTA [7] and STRICTOM [8] guidelines. Comparative analysis of the CARE, CARES, and CARC guidelines showed that these three guidelines contain quasi-identical items. Therefore, we propose the use of CARE [3,4] guidelines as the basic frame for pharmacopuncture intervention to be added to in order to compile pharmacopuncture case reporting guidelines for the future.
Although CONSORT [50]-based STRICTA [7] and STRICTOM [8] are guidelines for reporting RCT, their design focus on treatment interventions allowed items to be derived for pharmacopuncture case reporting. They are similar in overall details, with differences arising from the two different interventions mainly covered, i.e., acupuncture and moxibustion, respectively. Since pharmacopuncture case reporting guidelines should be compiled in line with the interventional characteristics specific to pharmacopuncture, the items specific to acupuncture and moxibustion were excluded. Then the following pharmacopuncture-specific items derived by analyzing the study results can be added: needling direction and depth, patient’s posture during the therapy, pharmacopuncture manufacturing methods, pharmacopuncture ingredients and composition, the diameter, length, and manufacturer, and total dose of pharmacopuncture administered per treatment session (Table 2 [7,8]). Regarding the items generally applicable to Korean medicine interventions (e.g., intervention type and treatment frequency), it is appropriate to follow these two guidelines. Moreover, “Other Treatment” (non-pharmacopuncture or concomitant treatments) of Korean medicine are usually practiced by combining various interventions, and it is recommended that they are considered items in “Therapeutic intervention” specific to CARC [9] which is suitable for complex interventions (Supplementary Table 1). These items include the name of the herbal medicine, administration method, administration path, manufacturer name, and manufacturing process (Supplementary Table 2 [1240]). Given that these proposals are based on a literature review, they need to be confirmed and/or supplemented by clinicians and methodology experts.
In this study, literature review-based proposals were made for a draft proposal of pharmacopuncture case reporting guidelines. However, there are several limitations to this study. Firstly, the proposals are based on a literature review of case studies rather than an expert committee proposing guidelines by recruiting clinical and research experts. In addition, the development of reporting guidelines should be confirmed using the Delphi technique. Based on the findings of this study, a committee of pharmacopuncture specialists from several associations should be formed. Research funding support is required for the Delphi studies. Secondly, by excluding the case series in the selection process because of the limitation of the research environments, the sample was limited to the case reports in Korea. This study’s proposed draft guideline should be reinforced with a feasibility study that is used for actual pharmacopuncture case studies. Lastly, Chinese herbal injection is often performed by intravenous administration and its clinical application of pharmacopuncture shows a different tendency from Korean clinical application [54]. It can be expected to be a more meaningful study if all the contents related to intravenous administration and Chinese research data used in clinical studies are included in the follow-up studies. In this study, we attempted to create a draft proposal for pharmacopuncture guidelines for practice in Korea. Follow-up research is required to create an extension for herbal injections, which is primarily conducted in China. Despite these limitations, this study is significant in that it identified the aspects of pharmacopuncture research in need of improvement by analyzing the current status of pharmacopuncture case reports and that it drew attention to the need to develop pharmacopuncture case reporting guidelines by making proposals for improving the reporting of existing pharmacopuncture case reports. The results of this study can serve as basic data for developing pharmacopuncture case reporting guidelines aiming at standardizing the reporting process and items. The results can be used in pharmacopuncture intervention reports of clinical studies with a high level of evidence, such as observational studies and controlled trials.
This study examined the report items of pharmacopuncture case reporting and evaluated the compliance of existing pharmacopuncture case reporting with those items. By analyzing the characteristics of the existing reporting guidelines we derived additional items to be included in pharmacopuncture case reporting guidelines to ensure reproducible pharmacopuncture case reporting. The items derived include: pharmacopuncture type, number of points treated during a treatment session, total dose per treatment session and single dose per point, acupoints and the rationale for selecting them, needling depth and direction, patient’s posture during the intervention, treatment environment, pharmacopuncture procedure and technique, and responses sought. This study is significant in that it drew attention to the need to develop pharmacopuncture case reporting guidelines and prepared basic data to develop them. Follow-up research is necessary for pharmacopuncture case reporting guideline development performed through discussion and consensus among experts.
Supplementary materials are available at doi:

Author Contributions

Conceptualization: GY. Formal analysis: SJ, CS, and HK. Investigation: SJ, CS, and HK. Methodology: SJ, CS, and HK. Project administration: JL. Supervision: HC. Validation: HC. Writing original draft: SJ, and CS. Writing-review and editing: JL.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Ethical Statement

This research is literature review that does not require IRB approval

Data Availability

All relevant data are included in this manuscript.


This research article was supported by Wonkwang University in 2022.

Fig. 1
Flow chart.
Table 1
Characteristic of Published Case Reports of Pharmacopuncture.
Study ID Disease/condition Patients characteristics Diagnostic assessment Treatment Outcome

Age/sex Chief complaint Duration Pharmacopuncture Other Measurement
An (2022) [12] Cervical Spondylotic Myelopathy 80/M - Rt. Hemiplegia
- Rt. Arm & Leg Pain
- Dysuria
ND 129d BVP Acp, HM, Pht, Drug 1) MMT 2) MBI 3) NRS

Jung (2020) [13] Systemic Lupus Erythematosus 44/F - Itching & Rash (Lower Body) Blood Test 302d BVP HM C3, C4 score

Kang (2021) [14] Traumatic Subarachnoid Hemorrhage, Injury of Oculomotor & Optic Nerve 54/M - Rt. Ptosis
- Rt. Eye movement disorder
- Pain of Neck, Shoulder, Back, Low Back, Anterior Chest
X-ray, Blood Test, ECG 41d BVP Acp, HM, Pht, Mox 1) NRS 2) Eye Movement Test

Jun (2021) [15] Diabetic Neuropathy 57/M - B/s. 4,5 Finger Numbness & Pain
- Sub-Knee Coldness
NCS 99d BVP Acp, HM, Etp, Mox, Drug 1) NPS 2) Peak Pain Frequency

An (2020) [16] Idiopathic Peripheral Neuropathy 26/M - Rt. Lower Body Muscle Weakness & Neuralgia X-ray, MRI, CT, NCS, Electromyography 74d BVP Acp, Etp 1) ROM 2) MMT 3) CLL 4) NPS

Lim (2020) [17] Brachial Plexus Palsy Whilst on Crutches 64/F - Weakness in Rt. Upper Limb Muscles & ROM Limits on the Rt. Wrist Joint X-ray 38d BVP, JSP Acp, HM 1) MMT 2) ROM 3) VAS

Kim (2018a) [18] Breast Cancer 74/F - Body Fatigue
- Arthralgia
Blood Test, Urinalysis, Liver Function Test 74d GP, BGP, BVP (Detoxification) Acp, HM, Mox 1) CTCAE* 2) ECOG

Cho (2019) [19] Acute Appendicitis 29/M - Nausea & Vomiting
- Anorexia
- Lower Abdominal Pain
PhE, Ultrasonography, Blood Test, Urinalysis 3d VYC ND 1) Symptom/Sign Progression 2) Ultrasonography

Chung (2019) [20] Hypoesthesia of Lower Limb 46/M - Lumbar Pain
- Rt. Lower Body Hypoesthesia
MRI, ROM, Lumbar Test 25d CP Acp, HM, Mox 1) NRS 2) ASIS Scale

Jin (2019) [21] Xerostomia 88/F - Xerostomia ND ND Normal Saline HM 1) 6-DDOD§ 2) 4-UBOD||

Kwon (2018) [22] Superior Labrum from Anterior to Posterior tear 68/M - Overall Pain in the Rt. Shoulder Joint
- Shoulder Girdle & Upper Arm
MRI, ROM 56d SBP HM, Cup, Pht, MSAT 1) VAS 2) ROM

Kim (2018b) [23] Tension-type Headache 39/M - Headache ND 27d BGP Acp, HM 1) NRS 2) HDI 3) Six Point Likert Scale

Kim (2021a) [24] L-HIVD 32/M - LBP
- Lt. Leg Radiating Pain
Blood Test, Urinalysis, SLR 22d SBP Acp, HM, Cup, Pht 1) NRS 2) ODI 3) EQ-5D

Lee (2021) [25] Acute Stress Disorder after Traffic Accident 26/F - Rt. Knee Pain
- Lt. Headache
- Anxiety
- Insomnia
X-ray 8d CKP HPP Acp, HM, Etp, Mox, Cup, Pct, ICT, CST, IR, Hangbang Pap 1) NRS 2) ROM 3) HEP 4) EFF 5) PCT 6) FFP 7) MCM 8) LJLT 9) MJLT 10) ADT 11) Lachman test 12) Varus/Valgus stress 13) BAI 14) PHQ-9 15) PSQI 16) CSEI-s 17) HRV(LF/HF)

Kim (2022) [26] Temporomandibular Disorder 54/F - Ear Pain During Mastication ND ND HPP Acp, Lcp 1) VAS 2) RDC/TMD

Ryu (2019) [27] Acute Herniated Lumbar Disc 37/M - Pain & Numb (Low Back, Buttock, Leg) X-ray, MRI, Blood Test, Urinalysis Electrocardiogram, PhE 26d SBP, BVP Acp, HM 1) NRS 2) ODI 3) EQ-5D 4) SLRT 5) Big Toe Extension

Kim (2020) [28] Non-Cardiac Chest Pain 48/F - Chest Pain X-ray, Blood Test, ECG, Myocardial SPECT 18d JOP Acp, HM, Mox, Drug 1) NRS 2) Chest Pain Frequency

Ahn (2019a) [29] Chronic Insomnia 46/F - Insomnia
- Rt. Facial Palsy
ND 20d HRP, BVP Acp, Etp, HM, Mox, Drug 1) PSQI-K 2) KSS 3) Daily Record of Sleep

Jeong (2019) [30] Grade Four Pressure Ulcer 39/M - Coccygeal Sore
- ICH at Pons
X-ray, MRI, Blood Test, ECG 96d HRP Acp, HM, Etp, Mox, Drug 1) Stage** 2) Extent†† 3) Cure rate‡‡ 4) Depth of Pressure Ulcer

Yoon (2019) [31] Non-Small Cell Lung Cancer 66/F - Pain (Gluteal Muscles, Isthmus, Chest, Abdomen) ND 216d ACDP Acp, HM, Mox, Cup 1) NRS 2) ECOG

Kim (2019) [32] Lumbago with Sciatica 39/M - LBP
- Lt. Thigh Pain
- Lt. Buttock Pain
- Gait Disorder
- Position Change Disorder
V/S, ROM, SLRT 21d HRP Acp, HM, Mox, Cup 1) VAS 2) ODI 3) SF-MPQ??

Ahn (2019b) [33] Rib Fracture 46/M - Left Side Pain Ultrasound, X-ray, CT 18d BVP Acp, Etp, Cup, Pht, Tap NRS

Lee (2018a) [34] Ulnar Tunnel Syndrome 59/M - Rt. Claw Hand & Motor Paralysis of 4,5th Finger Ultrasound 17d JOP HM, Etp, Pht 1) Adduction, Abduction (4,5th Finger) 2) Degree of Deformation Recovery of Claw Hands

Jeon (2021) [35] Chest Pain 75/M - Chest Pain 1) CT 2) ECG 15d JOP, BVP Acp, HM, Etp, Mox, Drug 1) FPS-R§§ 2) SF-MPQ|||| 3) KPPS¶¶ 4) Standing Position Evaluation

Lee (2018b) [36] Psoriasis 52/F - Itching
- Insomnia
ND 20d HRP Acp, HM, Drug 1) PASI*** 2) Pruritus Assessment

Kim (2021b) [37] Rt. Upper Body with Radial Nerve Palsy 46/M - Numbness & Weakness of Rt. Upper Body with Radial Nerve Palsy MRI, NCS, Electromyography, PhE††† 13d BVP Acp, HM, Etp, Mox, Cup, Drug 1) aROM 2) Grasp Strength Evaluation 3) Hypesthesia 4) VAS

Choi (2020) [38] Calcaneal Spur Syndrome 61/F - Plantalgia X-ray ND YGP Acp, Cup NRS

Park (2020) [39] Occipital Neuralgia 86/F - Headache
- Hip Pain
CT 55d HRP, BVP Acp, Etp, Mox, Cup, HM, Drug 1) FPS-R§§ 2) VAS 3) Frequency of Headaches 4) Area of a Headache 5) Headache Questionnaire

Jang (2020) [40] Restless Legs Syndrome 55/F - Uncomfortable Sensation & Pain in Both Legs X-ray, MRI, SLR, DTR Knee Jerk, DTR Ankle Jerk 8d SBP Acp, HM, Cup 1) NRS 2) K-IRLS††† 3) K-RLS QoL‡‡‡

* Common Toxicity Criteria for Adverse Event.

Eastern Cooperative Oncology Group.

Mcburney’s point pain, Tenderness, Rebound tenderness, Rovsingsign.

§ 6-DDOD: Six Questionnaires to Determine the Degree of Oral Dryness.

|| Four Questionnaire to Understand the Behavior of Oral Dryness.

ROM, SLR, Patrick, Bragard, Kernig, walking on the toe, Walking on the heel, Babinski, Valsalva, DTR, muscular disorder.

** Stage of Pressure.

†† Extent of Pressure.

‡‡ Cure rate of Pressure.

§§ Face Pain Scale-Revised.

|||| Short Form McGill Pain Questionnaire.

¶¶ King’s Parkinson’s Disease Pain Scale.

*** Psoriasis Area and Severity Index.

††† Tinel’s sign, Spurling test, Compression test, Adson’s test.

‡‡‡ International Restless Legs Scale.

§§§ Restless Legs Scale Quality of Life questionnaire.

ACP, acupuncture; ADT, anterior Drawer test; ASIA scale, American Spinal Injury Association scale; BAI, beck anxiety inventory; BGP, Byeol Gab pharmacopuncture; BVP, bee venom acupuncture; CLL, circumference of the lower limbs; CSEI-s, core seven emotions inventory scale; CT, computed tomography; CP, capsaicin containing pharmacopuncture; CST, craniosacral therapy; CUP, cupping therapy; ECG, electrocardiogram; EFF, effusion; EQ-5D, EuroQol-5 Dimension; ETp, electropuncture; FFP, frontal flexion position; GP, ginseng pharmacopuncture; HDI, Henry Ford Headache Disability Inventory; HRP, Hwangryunhaedok-tang pharmacopuncture; HRV, heart rate variability; HEP, hyperextension position; HPP, hominis placenta pharmacopuncture; ICT, interferential current therapy; IR, infrared; JOP, Jungsongouhyul pharmacopuncture; JSP, Juglandis Semen pharmacopuncture; KSS, Korean sleep scale; LCP, laser acupuncture; LJLT, lateral joint line tenderness; MCM, McMurray; MBI, modified barthel index; MRI, magnetic resonance imaging; MSAT, motion style acupuncture treatment; MMT, manual muscle testing; MOX, moxibustion; NCS, nerve conduction study; ND, not described; NRS, numeric rating scale; ODI, Oswestry disability index; PASI, psoriasis area and severity index; PCT, patella compression test; PHQ-9, patient health questionnaire; PHT, physiotherapy; PSQI, Pittsburgh Sleep Quality Index; PSQI-K, Korean version of Pittsburgh Sleep Quality Index; PST, psychotherapy; ROM, range of motion; SF-MPQ, the short-form McGill pain questionnaire; SBP, Shinbaro pharmacopuncture; SLRT, straight leg raising test; VAS, visual analogue scale; VYC, Yanggeumhwa pharmacopuncture.

Table 2
Proposal of Reporting Guideline for Pharmacopuncture in Case Reports.
Name STRICTA [7] STRICTOM [8] Suggestion about pharmacopuncture reporting
Treatment rationale (1a) Style of acupuncture (e.g., Traditional Chinese Medicine, Japanese, Korean, Western medical, Five Element, ear acupuncture, etc.)
(1b) Reasoning for treatment provided, based on historical context, literature sources and/or consensus methods, with references where appropriate
(1c) Extent to which treatment was varied
(1a) Type of moxibustion (e.g., direct moxibustion, indirect moxibustion, heat-sensitive moxibustion, moxa burner moxibustion, natural moxibustion)
(1b) Reasoning for treatment provided, based on historical context, literature sources, and/or consensus methods, with references where appropriate
(1c) Extent to which treatment was varied
1) Pharmacopuncture type
2) 3) Following existing guidelines
Details of treatment (2a) Number of needle injections per subject per session (mean and range where relevant)
(2b) Names (or location if no standard name) of points used (uni-/bilateral)
(2c) Depth of injection, based on a specified unit of measurement or on a particular tissue level
(2d) Responses sought (e.g., de qi or muscle twitch response)
(2e) Needle stimulation (e.g., manual or electrical)
(2f) Needle retention time
(2g) Needle type (diameter, length and manufacturer or material)
(2a) Materials used for moxibustion (e.g., moxa floss, moxa cone, moxa stick, herbal patches, and their sizes and manufacturers)
(2b) Names of acupoints (or location if no standard name) for moxibustion (uni/bilateral)
(2c) Number of moxibustion units and/or moxibustion time per point (mean and range where relevant)
(2d) Procedure and technique for moxibustion (e.g., direct/indirect, warming/sparrow-pecking technique, warming needle, moxa box, heat-sensitive moxibustion)
(2e) Responses sought (e.g., warm feeling, skin reddening, burning pain, heat-sensitization phenomenon)
(2f) Patient posture and treatment environment
1) Number of points treated during a treatment session
2) Total dose per session and single dose per point
3) Acupoint names (muscle or anatomical location) and the rationale for selection
4) Needling depth and direction
5) Patient’s posture during the therapy and treatment environment
6) Pharmacopuncture procedure and technique
7) Responses sought (patient’s perception or adverse effects)
1) Pharmacopuncture ingredients and composition
2) Pharmacopuncture manufacturing procedure (with all necessary details)
3) Pharmacopuncture manufacturing facilities (country, region)
4) Needle shape (diameter, length) and manufacturer
Treatment regimen (3a) Number of treatment sessions
(3b) Frequency and duration of treatment sessions
(3) Number, frequency, and duration of treatment sessions Following existing guidelines
Other components of treatment (4a) Details of other interventions administered to the acupuncture group (e.g., moxibustion, cupping, herbs, exercises, lifestyle advice)
(4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients
(4a) Details of other interventions administered to the moxibustion group (e.g., acupuncture, cupping, herbs, exercises, lifestyle advice)
(4b) Setting and context of treatment protocol, and information and explanations to patients
Not in line with the characteristics of case reporting
Practitioner background (5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience) (5) Description of treatment provider (qualification or professional affiliation, years in moxibustion practice and other relevant experience for professional, or any special training in advance for layman) Following existing guidelines
Additional items in CARC [8]
  • - Intervention name, manufacturer, product number, manufacturing method, manufacturing process

  • - The cultivation area of the intervention material, the quantity and quality of each material

  • - Intervention administration method, administration path

  • - Quality control standard

CARC, case report in Chinese medicine; STRICTA, standards for reporting interventions in clinical trials of acupuncture; STRICTOM, standards for reporting interventions in clinical trials of moxibustion.

  • [1] Byun DY, Kim H, Han SH, Kim KW, Lee JH, Chung WS, et al. Pharmacopuncture for lumbar herniated intervertebral disc: A systematic review and meta-analysis. Complement Ther Clin Pract 2021;43:101369. ArticlePubMed
  • [2] Hong K-E. Analysis study of survey for safety and efficacy of pharmacopuncture. J Pharmacopunct 2010;13(3):91−102.Article
  • [3] Rison RA. A guide to writing case reports for the Journal of Medical Case Reports and BioMed Central Research Notes. J Med Case Rep 2013;7:239. ArticlePubMedPMCPDF
  • [4] Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med 2013;2(5):38−43.ArticlePubMedPMCPDF
  • [5] Chu H, Kim Y, Min BK. A Guide to Writing a Case Report According to CARE Guideline. J Korean Med Soc Soft Tissue 2021;5(1):41−5.Article
  • [6] Nam E-Y, Park J-Y. Evaluation of the Quality of the Case Reports from the Journal of Obstetrics and Gynecology of Korean Medicine Based on the CARE Guidelines. J Korean Obstet Gynecol 2019;32(2):71−86.Article
  • [7] MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, et al. Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. PLoS Med 2010;7(6):e1000261.. ArticlePubMedPMC
  • [8] Cheng CW, Fu SF, Zhou QH, Wu TX, Shang HC, Tang XD, et al. Extending the CONSORT Statement to moxibustion. J Integr Med 2013;11(1):54−63.ArticlePubMed
  • [9] Fu S, Cheng C, Zhang L, Zhong L, Kun W, Lin J, et al. Consensus-based recommendations for case report in Chinese medicine (CARC). Chin J Integr Med 2016;22(1):73−9.ArticlePubMedPDF
  • [10] Lee S, Kim S-H, Han S-Y, Lee Y, Lee J, Bae N, et al. Development of guideline for reporting case report for Sasang medicine (CARES). J Sasang Const Med 2018;30(3):74−94.Article
  • [11] Kim JH, Jeong A, Lee HL. Assessment of the Quality of Reporting on Case Reports in Journal of Sasang Constitutional Medicine from June 2018 to December 2021: Using CARE Guideline. J Sasang Const Med 2022;34(1):13−27.Article
  • [12] An D, Kim C, Han S, Kim M, Yu J, Sun S. A Severe Cervical Spondylotic Myelopathy Patient Treated with Integrative Korean Medicine Including Acupuncture, Bee Venom Pharmacopuncture and Herbal Medicine: a case report. J Pharmacopunct 2022;25(2):138−44.ArticlePubMedPMC
  • [13] Jung J, Kim S. Case Report on Systemic Lupus Erythematosus Improved by Bee Venom Pharmacopuncture and Herb medicine. Korean Herb Med Info 2020;8(2):225−31.
  • [14] Kang J, Yang J, Chae I, Choi I, Jung E, Yoo H, et al. Case Report of Traumatic Subarachnoid Hemorrhage-Induced Oculomotor Nerve Palsy Treated with Korean Medicine, Including Sweet Bee Venom. J Intern Korean Med 2021;42(2):140−51.ArticlePDF
  • [15] Jeon G, Yim T, Hwang Y, Choi J, Park S, Park J, et al. A Case Report on Diabetic Neuropathy Treated with Bee Venom Acupuncture and Combined Korean Medicine. J Intern Korean Med 2021;42(5):958−66.ArticlePDF
  • [16] An S, Choi S, Kang S, Park S, Keum D. A Case of Idiopathic Peripheral Neuropathy Improved by Combined with Electroacupuncture and Bee Venom Acupuncture. J Korean Med Rehabil 2020;30(2):173−81.Article
  • [17] Lim JE, Song MS, Do HJ, Kim GH, Park JH, Yoon HM, et al. Brachial Plexus Palsy whilst on Crutches Treated with Korean Medicine Focused on Bee-Venom Pharmacopunture. J Acupunct Res 2020;37(4):270−4.ArticlePDF
  • [18] Kim M, Jung Y, Hong S. A Case Report of Cyclophosphamide plus Doxorubicin-induced Side effects in Patient with Both Sides Breast Cancer Treated with Integrative Medicine Therapy Including Pharmacopuncture. J Korean Tradit Oncol 2018;23(1):33−43.Article
  • [19] Cho S, Jung C, Kim K, Ko S, Jung H, Park J. A case study of acute appendicitis improved by pharmacopuncture treatment. J Intern Korean Med 2019;40(2):208−19.ArticlePDF
  • [20] Chung YJ, Lee H-J, Lee YK, Lee JH, Gong HM, Jun SA, et al. Case report of hypoesthesia of lower limb with additional CP pharmacopuncture. J Physiol Pathol Korean Med 2019;33(2):158−62.Article
  • [21] Jin J, Min B, Lee D, Seo H, Kim J. A Case Report of Spinal Pharmacopuncture and Herb Medicine for Dry Mouth. J Intern Korean Med 2019;40(2):262−9.ArticlePDF
  • [22] Kwon O-J, Kim G-H, Ju Y-G, Seo J-Y, Song K-C, Ryu W-H, et al. A case report of superior labrum from anterior to posterior tear patient treated with shinbaro pharmacopuncture and motion style acupuncture treatment (MSAT). J Korean Med Rehabil 2018;28(1):185−93.Article
  • [23] Kim Y, Kang E, Kim K. A case report of a patient with a tension-type headache treated by Korean medical treatment with Byeolgab pharmacopuncture. J Intern Korean Med 2018;39(5):870−8.ArticlePDF
  • [24] Kim S-J, Kim S-A, Kim M-K, Lee S-W, Kyung D-H, Bae J-E, et al. A Case Report inculding Pharmacopuncture Therapy at Lumbar Facet joints for a Patient with Lumbar Disc Herniation with Lower Back Pain and Leg Radiating Pain that Worsen during Pregnancy. J Korean Obstet Gynecol 2021;34(1):93−103.Article
  • [25] Lee D-E, Ha J-S, Park H-M, Youn I, Seo J-H. Clinical Approach of Chukyu Pharmacopuncture and Brainspotting Through a Traffic Accident Patient Case. J Orient Neuropsychiatry 2021;32(3):261−73.Article
  • [26] Kim M-H, Cho S-H. A case report of Placental Extract Herbal Acupuncture and Laser Theraphy for Patient with Temporomandibular Joint Disorder. J Korean Med Ophthalmol Otolaryngol Dermatol 2022;35(1):63−8.Article
  • [27] Ryu G, Moon H, Ju A, Choo W, Choi Y, Moon Y, et al. A Case Report on a Patient with Acute Herniated Lumbar Disc due to Coughing Treated with Megadose Pharmacopuncture and Combined Korean Medicine. J Intern Korean Med 2019;40(6):1248−58.ArticlePDF
  • [28] Kim S-Y, Choi J-W, Jeong H-S, Yim T-B, Ko C-N, Park J-M, et al. A Case Report of non-cardiac chest pain treated with Jungsongouhyul Pharmacopuncture and Insambaekhaokwanjung-tang. J Soc Stroke Korean Med 2020;21(1):1−10.
  • [29] Ahn S, Kim S, Kim J, Oh M, Nam D. A Case Report on a Patient with Chronic Insomnia Treated with Hwangryunhaedok-tang Pharmacopuncture. J Korea Immuno Yakchim Soc 2019;7(1):27−40.
  • [30] Jeong H-S, Kim H-R, Kim S-Y, Lee S-W, Cho S-Y, Park S-U, et al. A Clinical Case Report on Grade Four Pressure Ulcer Patients Treated with Hwangryunhaedok-tang Pharmacopunctue and Herbal Medicine Taklisodok-eum. J Soc Stroke Korean Med 2019;20(1):65−74.
  • [31] Yoon M, Cho N, Lee Y, Choi H, Kim S, Kim K. A Case Report of a Non-small Cell Lung Cancer Patient Metastasis to Vertebra with Cancer Pain Improved by Traditional Korean medicine including Aconitum Ciliare Decaisne Pharmacopuncture. J Korean Tradit Oncol 2019;24(2):33−41.Article
  • [32] Kim S-K, Kang S-J, Hong K-K, Choi C-M. A Clinical Case Report on Traditional Korean Medical Treatment Including Hwangryunhaedok-tang Pharmacopuncture for Low Back Pain with Sciatica during Pregnancy. J Korean Obstet Gynecol 2019;32(2):138−47.Article
  • [33] Ahn T-S, Moon J-H, Park C-Y, Oh M-J, Choi Y-M. The effectiveness of ultrasound-guided essential bee venom pharmacopuncture combined with integrative Korean medical treatment for rib fracture: a case study. J Korean Med Rehabil 2019;29(3):157−63.Article
  • [34] Lee H. A Case Report of Motor Paralysis of Ulnar Tunnel Syndrome Treated by Boyanghwano-tang(Buyanghaiwu-tang) Gagam and Jungsongouhyul Pharmacopuncture. J Sports Korean Med Clin Pharmacopunct 2018;18(1):23−31.
  • [35] Jeon G-R, Yim T-B, Hwang Y-C, Choi J-W, Cho S-Y, Park J-M, et al. A Case Report of Parkinson’s Patient Complaining of Chest Pain Treated with Jungsongouhyul Pharmacopuncture. J Soc Stroke Korean Med 2021;22(1):57−70.
  • [36] Lee H-C, Choi J-H, Kim J-H, Jeong M-Y, Park S-Y. A Case Report of Psoriasis treated with Traditional Korean Medicine Including SaengRyoSaMultang-Gamibang and Hwangryunhaedok-tang Herbal-Acupuncture. J Korean Med Ophthalmol Otolaryngol Dermatol 2018;31(1):106−16.Article
  • [37] Kim E, Nam D. A Case Report on Numbness and Weakness of Rt. Upper extremity with Radial Nerve Palsy Treated mainly with Bee Venom treatment with combined treatment of Korean medicine. J Sports Korean Med Clin Pharmacopunct 2021;21(1):41−50.
  • [38] Choi S. The Improvement of Platalgia with the Datura Metel L. Pharmocopuncture. Korean Med Soc Acupotomol 2020;4(1):99−103.
  • [39] Park K, Nam D, Hong Y. A case report of Hwangryunhaedok-tang pharmacopuncture for a patient with occipital neuralgia. J Spine Joint Korean Med 2020;17(1):143−56.
  • [40] Jang S, Jun H, Kim S, Kim M, Yoo J, Kim Y, et al. The Effect of Complex Korean Medical Treatment with Pharmacopuncture on Restless Legs Syndrome: A Case Report. J Spine Joint Korean Med 2020;17(1):61−9.
  • [41] Park JE, Kim KH, Kang S, Lee EK, Kim J-C, Jang B-H, et al. Usage status and satisfaction with pharmacopuncture in Korea: A survey among Korean medicine doctors. Eur J Integr Med 2019;27:121−30.Article
  • [42] Yin CS, Koh HK. The first documental record on bee venom therapy in Oriental medicine: 2 prescriptions of bee venom in the ancient Mawangdui books of Oriental medicine. Korea Acupunct Moxibustion Soc 1998;15(1):143−7.
  • [43] Han C-H, Lee Y-S, Kwon O-M, Lee Y-J. The Review on the Study of Bee Venom in the Journals of Korean Medicine. Korean J Acupunct 2013;30(1):27−36.Article
  • [44] Son C, Cho S, Park H, Moon S. The Assessment of Reporting Interventions in Randomized Controlled Trials of Acupuncture according to the STRICTA Recommendation. Korean J Acupunct 2006;23(2):59−67.
  • [45] Kim SY, Lee EJ, Jeon JH, Kim JH, Jung IC, Kim YI. Quality Assessment of Randomized Controlled Trials of Moxibustion Using STandards for Reporting Interventions in Clinical Trials of Moxibustion (STRICTOM) and Risk of Bias (ROB). J Acupunct Meridian Stud 2017;10(4):261−75.ArticlePubMed
  • [46] Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes 2014;7:264. ArticlePubMedPMCPDF
  • [47] Richason TP, Paulson SM, Lowenstein SR, Heard KJ. Case reports describing treatments in the emergency medicine literature: missing and misleading information. BMC Emerg Med 2009;9:10. ArticlePubMedPMCPDF
  • [48] Grimes DA, Schulz KF. Descriptive studies: what they can and cannot do. Lancet 2002;359(9301):145−9.ArticlePubMed
  • [49] Freer R, Rowett A, Camm CF. An assessment of adherence to CARE reporting standards by case reports published in European Heart Journal - Case Reports in 2018. Eur Heart J Case Rep 2020;4(5):1−5.ArticlePubMedPMCPDF
  • [50] Schulz KF, Altman DG, Moher D; the CG. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010;8:18. ArticlePubMedPMCPDF
  • [51] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61(4):344−9.ArticlePubMed
  • [52] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.. ArticlePubMedPMC
  • [53] Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687.. ArticlePubMed
  • [54] Li H, Wang S, Yue Z, Ren X, Xia J. Traditional Chinese herbal injection: Current status and future perspectives. Fitoterapia 2018;129:249−56.ArticlePubMed

Figure & Data



    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        • Citation for the content below
        Proposal of a Case Reporting Draft Guideline for Pharmacopuncture: Literature Review of Pharmacopuncture Case Reports
        Perspect Integr Med. 2023;2(1):24-35.   Published online February 21, 2023
      • XML DownloadXML Download

      Perspect Integr Med : Perspectives on Integrative Medicine